Japan approves Eylea for myopic CMV

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Japan's Ministry of Health, Labor and Welfare approved Eylea aflibercept to treat myopic choroidal neovascularization (myopic CNV), the second leading cause of blindness in Japan. Bayer AG (Xetra:BAYN) holds ex-U.S. rights to Eylea from Regeneron. The drug is a human fusion protein that binds all forms of VEGF-A and placental growth factor ( PGF; PlGF). ...